4/A: Tvardi Therapeutics Director Amends Filing to Correct Transaction Code After Merger

Wallace L. Hall Jr., a director of Tvardi Therapeutics, files an amended Form 4 to correct an initial error in the transaction code related to the acquisition of common stock following the merger with Legacy Tvardi.

Summary

• Wallace L. Hall Jr., a director of Tvardi Therapeutics, filed an amended Form 4 with the SEC on May 2, 2025, to correct a previously reported transaction.
• The amendment pertains to transactions occurring on April 15, 2025, related to the merger between Cara Therapeutics, Inc. (now Tvardi Therapeutics, Inc.) and Legacy Tvardi.
• The corrected filing reflects the acquisition of 44,712 shares of common stock indirectly through Firepit Partners, LP, and 202,044 shares indirectly through BioMatrix Partners Ltd.
• These shares were received in exchange for Series A and Series B Preferred Stock of Legacy Tvardi and convertible notes, pursuant to the merger agreement.
• The initial Form 4 inadvertently listed an incorrect transaction code, which this amendment rectifies.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing (Form 4/A) to correct a minor error. It doesn't indicate any significant positive or negative developments for the company, but the correction itself is a positive sign of diligence.

Negatives

• The initial Form 4 filing contained an incorrect transaction code, necessitating an amendment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The correction of the filing ensures accurate information for shareholders and potential investors.

Key Dates

Keywords

Tvardi Therapeutics, Form 4, Amendment, Merger, Wallace L. Hall Jr., Firepit Partners, BioMatrix Partners, SEC Filing, Beneficial Ownership, TVRD